Nanopharmaceuticals (part 2): products in the pipeline
Volkmar Weissig, Diana Guzman-VillanuevaDepartment of Pharmaceutical Sciences, Midwestern University College of Pharmacy Glendale, Glendale, AZ, USAAbstract: In part I of this review we assessed nanoscience-related definitions as applied to pharmaceuticals and we discussed all 43 currently approved...
Guardado en:
Autores principales: | Weissig V, Guzman-Villanueva D |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9e3500fd156c48afb882e6a47953bbea |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Nanopharmaceuticals (part 1): products on the market
por: Weissig V, et al.
Publicado: (2014) -
Use of electrical impedance spectroscopy to detect malignant and potentially malignant oral lesions
por: Murdoch C, et al.
Publicado: (2014) -
Undetactable levels of genotoxicity of SiO2 nanoparticles in in vitro and in vivo tests [Erratum]
por: Kwon JY, et al.
Publicado: (2015) -
Silk fibroin nanoparticles constitute a vector for controlled release of resveratrol in an experimental model of inflammatory bowel disease in rats
por: Lozano-Pérez AA, et al.
Publicado: (2014) -
Injectable long-acting systems for Radix Ophiopogonis polysaccharide based on mono-PEGylation and in situ formation of a PLGA depot
por: Shi XL, et al.
Publicado: (2014)